CN108434440B - 多肽疫苗 - Google Patents

多肽疫苗 Download PDF

Info

Publication number
CN108434440B
CN108434440B CN201810214453.2A CN201810214453A CN108434440B CN 108434440 B CN108434440 B CN 108434440B CN 201810214453 A CN201810214453 A CN 201810214453A CN 108434440 B CN108434440 B CN 108434440B
Authority
CN
China
Prior art keywords
cancer
prl
intracellular
peptide
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810214453.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108434440A (zh
Inventor
曾琦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG2012011581A external-priority patent/SG193038A1/en
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of CN108434440A publication Critical patent/CN108434440A/zh
Application granted granted Critical
Publication of CN108434440B publication Critical patent/CN108434440B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201810214453.2A 2011-09-06 2012-08-29 多肽疫苗 Active CN108434440B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161531290P 2011-09-06 2011-09-06
US61/531,290 2011-09-06
SG2012011581A SG193038A1 (en) 2012-02-17 2012-02-17 Polypeptide vaccine
SG201201158-1 2012-02-17
SG2012046447 2012-06-21
SG201204644-7 2012-06-21
CN201280054509.3A CN103987396A (zh) 2011-09-06 2012-08-29 多肽疫苗
PCT/SG2012/000305 WO2013036201A1 (en) 2011-09-06 2012-08-29 Polypeptide vaccine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280054509.3A Division CN103987396A (zh) 2011-09-06 2012-08-29 多肽疫苗

Publications (2)

Publication Number Publication Date
CN108434440A CN108434440A (zh) 2018-08-24
CN108434440B true CN108434440B (zh) 2022-08-23

Family

ID=54259018

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810214453.2A Active CN108434440B (zh) 2011-09-06 2012-08-29 多肽疫苗
CN201280054509.3A Pending CN103987396A (zh) 2011-09-06 2012-08-29 多肽疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280054509.3A Pending CN103987396A (zh) 2011-09-06 2012-08-29 多肽疫苗

Country Status (6)

Country Link
US (2) US10258676B2 (https=)
EP (1) EP2753345B1 (https=)
JP (2) JP6153526B2 (https=)
CN (2) CN108434440B (https=)
SG (2) SG11201400432VA (https=)
WO (1) WO2013036201A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2759015T3 (es) 2010-02-10 2020-05-07 Mayo Found Medical Education & Res Métodos y materiales para tratar el cáncer
US20140005119A1 (en) * 2012-06-28 2014-01-02 Case Western Reserve University COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
WO2014024965A1 (ja) * 2012-08-10 2014-02-13 学校法人 久留米大学 上皮成長因子受容体のt790m点突然変異配列に由来する抗原ペプチド
US20170049870A1 (en) * 2012-08-10 2017-02-23 Kanagawa Prefectural Hospital Organization Antigen Peptide Derived From the Sequence of Epidermal Growth Factor Receptor Having T790M Point Mutation
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015143221A1 (en) * 2014-03-19 2015-09-24 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10188713B2 (en) 2014-03-19 2019-01-29 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CA2954279C (en) * 2014-07-07 2023-11-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
SG10201404895XA (en) * 2014-08-13 2016-03-30 Agency Science Tech & Res Diagnosis
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
IL294183B2 (en) * 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
US11253580B2 (en) * 2016-01-07 2022-02-22 Duke University Cancer vaccines and methods of delivery
US12220451B2 (en) * 2016-02-04 2025-02-11 Duke University Cell-based vaccine compositions and methods of use
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
AU2019403393B2 (en) * 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
WO2020145222A1 (ja) * 2019-01-07 2020-07-16 地方独立行政法人神奈川県立病院機構 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬
CN114981409A (zh) 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
EP4056197A4 (en) * 2019-11-07 2023-09-06 Shenzhen Gino Biotechnology Co., Ltd. TUMOR-SPECIFIC POLYPEPTIDE SEQUENCE AND USE THEREOF
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN111072763A (zh) * 2019-12-23 2020-04-28 维塔恩(广州)医药有限公司 肿瘤相关基因gnas突变相关抗原短肽及其应用
CN111393509B (zh) * 2020-03-30 2022-03-29 国家纳米科学中心 靶向特异性多肽及其应用
CN111285935B (zh) * 2020-05-13 2020-09-11 方达医药技术(上海)有限公司 特异性检测braf基因突变的抗体及其在制备癌症检测试剂盒中的用途
US12516307B2 (en) 2020-08-18 2026-01-06 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
US20240287149A1 (en) * 2021-05-14 2024-08-29 Oslo University Hospital Mutated gnas peptides
CN116139253B (zh) * 2021-08-10 2025-04-22 昆明医科大学 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007110098A1 (en) * 2006-03-29 2007-10-04 Institut National De La Sante Et De La Recherche Medicale HBx PEPTIDES, CAPABLE OF ELICITING A PROMISCUOUS IMMUNODOMINANT CD4+ RESPONSE DIRECTED AGAINST HBV
WO2008008311A1 (en) * 2006-07-10 2008-01-17 The Trustees Of The University Of Pennsylvania Methods for administering tumor vaccines
WO2011065923A1 (en) * 2009-11-30 2011-06-03 Agency For Science, Technology And Research Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
EP0534615B1 (en) * 1991-08-26 2001-01-03 Epimmune Inc. HLA-restricted hepatitis B virus CTL epitopes
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO1996018409A1 (en) * 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US6514942B1 (en) 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
WO2001062969A2 (en) 2000-02-22 2001-08-30 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
US7105642B2 (en) 2001-08-03 2006-09-12 Cell Signalling Technology, Inc. Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
EP1712620A4 (en) 2004-01-23 2008-05-28 Greenpeptide Co Ltd EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR-ORGANIC PEPTIDE
CN103285392A (zh) * 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
WO2006120038A2 (en) * 2005-05-09 2006-11-16 Vaxon Biotech Use of native peptides and their optimized derivatives for vaccination
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
EP2150276B1 (en) * 2007-05-03 2014-05-21 Agency For Science, Technology And Research Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
US8765388B2 (en) * 2007-08-10 2014-07-01 Agency For Science, Technology And Research (A*Star) VHZ for diagnosis and treatment of cancer
KR100995340B1 (ko) * 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
WO2010016806A1 (en) * 2008-08-08 2010-02-11 Agency For Science, Technology And Research (A*Star) Vhz for diagnosis and treatment of cancers
US8524669B2 (en) * 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
WO2012049229A1 (en) 2010-10-15 2012-04-19 Université Libre de Bruxelles Estrogen receptor alpha polypeptide sequence, diagnostic and therapeutic applications thereof
CN102675424B (zh) 2011-03-15 2014-02-05 天津托普泰克生物科技有限公司 抗乙型肝炎病毒x蛋白多肽药物
CN102675422B (zh) 2011-03-15 2014-02-05 天津托普泰克生物科技有限公司 抗乙型肝炎病毒x蛋白多肽药物
CN102675423B (zh) 2011-03-15 2014-02-05 天津托普泰克生物科技有限公司 抗乙型肝炎病毒x蛋白多肽药物
EP2562205A1 (de) * 2011-08-22 2013-02-27 Rhein Chemie Rheinau GmbH Neue Folien für Solarzellen
CN102357246B (zh) 2011-11-02 2013-04-03 江苏省中医药研究院 一种egfr与her2联合多肽表位疫苗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007110098A1 (en) * 2006-03-29 2007-10-04 Institut National De La Sante Et De La Recherche Medicale HBx PEPTIDES, CAPABLE OF ELICITING A PROMISCUOUS IMMUNODOMINANT CD4+ RESPONSE DIRECTED AGAINST HBV
WO2008008311A1 (en) * 2006-07-10 2008-01-17 The Trustees Of The University Of Pennsylvania Methods for administering tumor vaccines
WO2011065923A1 (en) * 2009-11-30 2011-06-03 Agency For Science, Technology And Research Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AF041434;NCBI;《GenBank》;19980809;全文 *
CBX46805;NCBI;《GenPept》;20110125;全文 *
development and characterization of monoclonal antibodies to a specific domain of human estrogen receptor;Abdulmaged M. Traish等;《Steroids》;19901231;第196-208页 *
NP_004439;NCBI;《GenPept》;20110821;全文 *

Also Published As

Publication number Publication date
SG10201903119QA (en) 2019-05-30
US20200101147A1 (en) 2020-04-02
JP2017186352A (ja) 2017-10-12
EP2753345A1 (en) 2014-07-16
EP2753345A4 (en) 2015-03-25
US20150306196A1 (en) 2015-10-29
CN103987396A (zh) 2014-08-13
EP2753345B1 (en) 2016-07-13
US10258676B2 (en) 2019-04-16
JP6153526B2 (ja) 2017-06-28
JP6676584B2 (ja) 2020-04-08
SG11201400432VA (en) 2014-08-28
JP2014526462A (ja) 2014-10-06
CN108434440A (zh) 2018-08-24
WO2013036201A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
CN108434440B (zh) 多肽疫苗
US11981748B2 (en) Methods for inhibiting angiogenesis in a subject in need thereof
CN101820910B (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
US12404341B2 (en) Glypican-3 (GPC-3) antibodies
EP2506864B1 (en) Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
CN103037896B (zh) 癌胚抗原的n‑结构域及其组合物、方法和用途
US20130058979A1 (en) Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
SG193038A1 (en) Polypeptide vaccine
OA19004A (en) Methods for inhibiting angiogenesis in a subject in need thereof.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant